Celator Raises Another $4.15M to Fuel Synergistic Cancer Treatment
September 4, 2012
Celator Pharmaceuticals, a developer of advanced cancer treatments, has tapped investors for $4.15 million of a planned $35 million round. Based in Princeton, New Jersey, Celator creates synergistic ratios of drugs to more effectively kill tumor cells. The most recent financing brings the company’s total venture backing to $104.15 million. Previous investors in Celator include BDC Venture Capital, GrowthWorks and Domain Associates.